



Upregulation of glycolytic enzyme PFKFB3 by deubiquitinase OTUD4 promotes cardiac fibrosis post myocardial infarction

Feizuo Wang^{1,2} · Xiaojian Yin² · Yuan-Ming Fan² · Xinyao Zhang² · Chao Ma¹ · Keke Jia¹ · Wei Zhou² · Zongxiang Tang¹ · Lian-Wen Qi² · Jia Li¹

Received: 4 November 2022 / Revised: 22 March 2023 / Accepted: 14 April 2023
© The Author(s) 2023

Abstract

Metabolic dysregulations have emerged as a major mediator of cardiovascular disorders and fibrotic diseases. Metabolic reprogramming contributes a lot to cardiac fibroblast activation and cardiac fibrosis post-myocardial infarction (MI), yet the mechanism remains incompletely understood. Our work aimed to determine whether or not glycolytic reprogramming, regulated by phosphofructokinase-2/fructose-2,6-bisphosphatase 3 (PFKFB3), is a therapeutic target for alleviating post-MI cardiac fibrosis. Here, we showed that cardiac fibroblasts displayed cell energy phenotype toward augmented glycolysis in response to transforming growth factor-beta 1 (TGF- β 1), evidenced by significant extracellular acidification rate (ECAR) increase and lactate accumulation. The expression of glycolytic enzyme PFKFB3, a master activator of glycolysis, was up-regulated in TGF- β 1-treated cardiac fibroblasts and in cardiac fibroblasts of post-MI mice. Pharmacological inhibition of PFKFB3 by 3PO diminished TGF- β 1-mediated profibrotic phenotypes, attenuated cardiac fibrosis, and preserved cardiac functions in post-MI mice. Meanwhile, the genetic inhibition of PFKFB3 decreased the cardiac fibroblast activation and reversed the differentiated phenotypes in vitro and in vivo. Mechanistically, we identified deubiquitinase OTUD4 as a new binding protein of PFKFB3, and their interaction blocked PFKFB3 degradation via OTUD4-mediated deubiquitylation. Taken together, this work characterized a key role for PFKFB3 in cardiac fibroblast activation and suggested that inhibiting PFKFB3-involved glycolysis is an alternative way to alleviate post-MI cardiac fibrosis.

Key messages

- PFKFB3, a master activator of glycolysis, was highly expressed in ischemic cardiac fibroblasts to enhance cardiac fibrosis
- The deubiquitinase OTUD4 was identified as a new binding protein of PFKFB3
- TGF- β 1 blunted the ubiquitination-mediated degradation of PFKFB3 via OTUD4-mediated deubiquitylation
- Blockade of PFKFB3 contributed to ameliorating ischemia-induced cardiac fibrosis

Keywords Cardiac fibrosis · Glycolysis · Metabolic reprogramming · OTUD4 · PFKFB3

Introduction

Cardiac fibrosis is a crucial aspect of remodeling of the failing heart, characterized by abnormal proliferation of interstitial fibroblasts and excessive deposition of extracellular

matrix (ECM). After the ischemic injury, the damaged cardiomyocytes are replaced by fibrotic scars due to limited regenerative capacity. During the repair process, cardiac fibroblasts are activated and exhibit proliferative and secretive characteristics to prevent the rupturing of the ventricular wall [1, 2]. Excessive and sustained forces of cardiac fibroblast activation, however, could increase left ventricle stiffness and decrease ventricular wall compliance, resulting in impaired cardiac output [2]. Given that fibroblasts act as the critical mediator cells concerning pathological reactive fibrosis, targeting the activated cardiac fibroblasts may represent a strategy to prevent ischemia-induced cardiac fibrosis and heart failure.

Feizuo Wang and Xiaojian Yin contributed equally to this work.

✉ Zongxiang Tang
zongxiangtang@njucm.edu.cn

✉ Lian-Wen Qi
qilw@cpu.edu.cn

✉ Jia Li
460184@njucm.edu.cn

Extended author information available on the last page of the article

Metabolic alterations are implicated in the pathogenesis of various diseases, such as cancer and cardiovascular diseases [3, 4]. A hallmark feature of metabolic reprogramming is the enhancement of aerobic glycolysis [5]. In cancer cells, aerobic glycolysis can produce ATP faster, and the increased glycolytic flux also generates byproducts to fuel proliferation [6]. Increasing evidence indicates that Warburg effects also act as a crucial role in non-tumor disease, including cardiac hypertrophy and failing heart [7, 8]. Indeed, increased glucose uptake and lactate production are also observed in proliferating non-cancer cells [9]. In fibrosis, metabolic reprogramming is required for myofibroblast contractility and differentiation [10]. Glycolysis has been demonstrated to be essential for regulating transforming growth factor beta 1 (TGF- β 1) secretion and its downstream signalings [11]. Glycolysis is also necessary for ECM production in terms of amino acid synthesis, collagen hydroxylation, and ECM secretion [11, 12]. When the heart suffers ischemia, glycolysis is enhanced to supply amounts of energy quickly [13].

Glycolysis is a multi-step reaction that is controlled by several rate-limiting glycolytic enzymes, including hexokinase (HK), phosphofructokinase (PFK), and pyruvate kinase (PK). Targeting these rate-limiting glycolytic enzymes is an ideal strategy for limiting cardiac fibrosis. However, direct inhibition of these enzymes may result in complete blockade of glycolytic flux and thus cause unfavorable effects [14], since they are indispensable for the remodeling of the cardiac tissue after ischemic injury [15]. Phosphofructokinase-2/fructose-2,6-bisphosphatase 3 (PFKFB3) is a master activator of glycolysis, which synthesizes fructose-2,6-bisphosphate (F2,6BP), an allosteric activator of PFK1 [16]. Among all four PFKFB bifunctional isoenzymes, PFKFB3 has a much higher kinase activity than bisphosphatase activity to shunt glucose toward glycolysis [17]. PFKFB3 blockade could inhibit glycolysis partially and transiently, indicating its therapeutic potential [18]. PFKFB3 is highly expressed in many cancer cells and proliferating non-cancer cells [19]. The PFKFB3 protein level is affected by synthesis and degradation [20–22]. Its protein stability is controlled by the ubiquitin-dependent proteasomal pathway [22]. The role of PFKFB3-involved glycolysis in cardiac fibroblast activation after ischemic damage remains to be investigated.

This work sought to characterize the role of PFKFB3 in post-MI cardiac fibrosis. We observed a noticeable increase of PFKFB3 and glycolysis in TGF- β 1-stimulated cardiac fibroblasts *in vitro* and in the hearts of post-MI mice. Genetic silencing and pharmacological inhibition were employed to investigate the functions of PFKFB3 in cardiac fibrosis. Co-immunoprecipitation combined with mass spectrometry (Co-IP/MS) was performed to identify PFKFB3-binding proteins and to explore the underlying mechanisms.

Materials and methods

For additional experimental procedures, see Supplemental Methods.

Animals and experimental model

C57BL/6 J male mice (6–8 weeks) were purchased from the Laboratory Animal Center of GemPharmatech Co. Ltd. (Nanjing, China). The mice were subjected to permanent ligation of the left anterior descending coronary artery (LAD) as described previously [23]. After surgery, 3PO (35 mg/kg) or vehicle (DMSO) was administered by intraperitoneal injection every other day for 4 weeks. For knock-down PFKFB3, mice received a single-bolus AAV9-*Pfkfb3* shRNA or AAV9-NC (Hanbio Biotechnology, Shanghai, China) via tail vein injection, which may show clear silencing efficacy 2–4 weeks after infusion. After confirmation of successful *pfkfb3* knockdown 3 weeks after AAV-shRNA injection, LAD ligation surgery was conducted. A cardiac function assay was conducted 4 weeks post-myocardial infarction (MI). Then the hearts were isolated for Masson's trichrome staining, picrosirius red staining, immunohistochemistry examination, or protein extraction. The animal care and all experimental procedures were approved by the Animal Ethics Committee of the Nanjing University of Chinese Medicine and the Animal Ethics Committee of China Pharmaceutical University.

Cell preparation and culture

Neonatal rat cardiac fibroblasts (NRCFs) were isolated from 1- to 2-day-old SD rats from B&K Universal Group Ltd (Shanghai, China) following a reported method [24]. The prepared fibroblasts were treated with TGF- β 1 (10 ng/ml) with or without PFKFB3 inhibitor 3PO (20 μ M) for 24 h. For silencing *Pfkfb3*, the cardiac fibroblasts were transfected with siRNA specific for rat *Pfkfb3* (Hanbio Biotechnology) using Lipofectamine 3000 (Invitrogen, USA). After transfection, cells were stimulated with TGF- β 1 (10 ng/ml) for 24 h.

Cell energy phenotype test

NRCFs were plated in Seahorse XF Cell Culture Microplate and treated with or without TGF- β 1 for 24 h. The extracellular acidification rate (ECAR) and mitochondrial oxygen consumption rate (OCR) of NRCFs were assayed by Agilent Seahorse XF Cell Energy Phenotype Test Kit (Seahorse Bioscience Inc., North Billerica, USA).

Western blot assay

After indicated treatment, NRCFs were lysed. Equivalent amounts of protein were separated by SDS-PAGE and transferred onto PVDF membranes. After blocking, the membranes were incubated with primary antibodies, followed by incubation with HRP-conjugated secondary antibodies. The relative expression level of the target protein was normalized to housekeeping gene α -Tubulin content. The blots were quantified by ImageProPlus 6.0 software. The information for antibodies was shown in the Supplemental Methods.

Co-immunoprecipitation assay

After being treated with TGF- β 1 for 24 h, NRCFs were lysed by Pierce IP Lysis Buffer (Thermo Fisher Scientific). After centrifugation, part of the supernatant was taken out as input. The remaining supernatant was incubated overnight with either PFKFB3-specific polyclonal antibody (Proteintech, 13763-1-AP) or OTUD4 antibody (Novus Biologicals, NBP1-36976). Afterward, the lysates were treated with Pierce Protein A/G Magnetic Beads (Thermo Fisher Scientific). Bead-bound proteins were resolved by SDS-PAGE and detected by immunoblotting.

Immunofluorescence

NRCFs were co-transfected with Flag-PRKFB3 and HA-OTUD4 plasmids (Hanbio Biotechnology). After being treated with or without TGF- β 1 for 24 h, cells were fixed by 4% paraformaldehyde and then blocked by Quick-Block™ Blocking Buffer for Immunol Staining (Beyotime). Afterward, the cells were incubated by DYKD-DDDK tag Monoclonal antibody (Binds to FLAG® tag epitope) (Proteintech, 66008-4-Ig) and HA tag Polyclonal antibody (Proteintech, 51064-2-AP) overnight. Alexa Flour 647 conjugated antibody and Alexa Flour 488 conjugated antibody were employed to visualize the proteins. Images were acquired with a confocal microscope (CLSM, LSM700, Zeiss, Germany).

Proximity ligation assay

Duolink assay Duolink® proximity ligation assay (PLA®) (Sigma-Aldrich; DUO92101) was performed according to the manufacturer's instructions. In brief, NRCFs were treated with or without TGF- β 1 for 24 h. After fixation and blocking, cells were incubated with PFKFB3-specific antibody (Proteintech, 13763-1-AP) and anti-OTUD4 antibody

(LSBio, LS-C669427), washed with PBS, applied with PLA minus and plus probes, continued with ligation and amplification. Images were acquired with a confocal microscope (CLSM, LSM700, Zeiss).

Surface plasmon resonance (SPR) analysis

The binding affinity between PFKFB3 and OTUD4 was assayed by a Biacore T200 (GE Healthcare). OTUD4 human recombinant protein (Origene Technologies, Inc., Rockville, MD, USA) was captured on a CM5 chip by a typical amine coupling procedure. Binding sensorgrams were recorded by injecting various concentrations of PFKFB3 solution (Origene) over the immobilized OTUD4 surface. The data were fitted and analyzed to obtain the equilibrium dissociation constant (KD) value.

Statistical analysis

The data were expressed as mean \pm SD. All experiments were performed at least four times. Significant differences were analyzed by one-way ANOVA followed by Bonferroni correction using GraphPad Prism 7. *p*-value < 0.05 was considered statistically significant.

Results


Glycolysis was augmented in cardiac fibroblasts upon TGF- β 1 stimulus

To investigate if the pathogenesis of cardiac fibrosis involves metabolic reprogramming, we determined the energy phenotype profile of NRCFs differentiated with fibrotic activator TGF- β 1. Seahorse extracellular flux analyzer showed that TGF- β 1 stimulation led to a significant ECAR increase, an indicator of glycolysis, both in baseline and stressed phases. OCR, a representation of mitochondrial oxidative phosphorylation, is also elevated in response to TGF- β 1 (Fig. 1a). Meanwhile, TGF- β 1 stimulation increased lactate accumulation (Fig. 1b), a metabolic product of glycolysis, and elevated cytosolic NADH/NAD⁺ ratio (Fig. 1c).

Glycolytic enzyme PFKFB3 was elevated in fibrotic cardiac fibroblasts

We investigated several glycolytic enzymes in TGF- β 1-induced NRCFs that might contribute to the energy phenotype changes. The mRNA expressions of *Hk2*, *Pfkfb3*, *Pfkf3*, and *Pkm2* were significantly increased (Fig. 2a).

Fig. 1 Glycolysis was augmented in cardiac fibroblasts upon TGF- β 1 stimulus. **a** Energy phenotypes, mitochondrial oxygen consumption rate, and extracellular acidification rate of neonatal rat cardiac fibroblasts stimulated by TGF- β 1 (10 ng/ml, 24 h) assayed in quiescent and stressed conditions ($n=6$). **b** Lactate levels in cultural supernatant of neonatal rat cardiac fibroblasts subjected to TGF- β 1 (10 ng/ml, 24 h) ($n=6$). **c** NADH/NAD⁺ ratio in neonatal rat cardiac fibroblasts subjected to TGF- β 1 (10 ng/ml, 24 h) ($n=6$). Data were expressed as mean \pm SD. ECAR, extracellular acidification rate; OCR, oxygen consumption rate; NAD, nicotinamide adenine dinucleotide; TGF- β 1, transform growth factor β 1



Considering that direct inhibition of key rate-limiting glycolytic enzymes (HK, PFK1, PKM2) may cause unfavorable effects, we focused on PFKFB3, a key modulator of glycolysis. RNA sequencing database (GSE132143) of human cardiac tissue from ischemic patients confirmed that *PFKFB3* expression was up-regulated (Fig. 2b). Consistently, single-cell RNA sequencing database also demonstrated that *Pfkfb3* expression exhibited an increasing trend in the cardiac fibroblasts from mice 7, 14, and 30 days post infarction (Fig. 2c). Additionally, there was a positive correlation between the *Pfkfb3* and fibrotic markers (Fig. 2d). In line with these results, our experiments showed that PFKFB3 exhibited a low basal level of protein expression but was strongly increased in primary adult cardiac fibroblasts isolated from mice 4 weeks post-MI (Fig. 2e, Supplemental Fig. S1a), but not in cardiomyocytes or infiltrating macrophages (Supplemental Fig. S1b, c). Consistently, PFKFB3 was also elevated in NRCFs subjected to TGF- β 1 (Fig. 2f).

Inhibition of PFKFB3-involved glycolysis alleviated the fibrotic phenotypes in TGF- β 1-induced cardiac fibroblasts

To investigate the effect of augmented glycolysis on the activation and differentiation of cardiac fibroblasts, we used a specific PFKFB3 inhibitor 3PO to attenuate glycolysis at the given concentration without any cytotoxic effects on cardiomyocytes (Supplemental Fig. S2a). 3PO treatment impaired PFKFB3 enzyme activity, reflected by the activity of phosphofruktokinase (Fig. 3a) and reduced extracellular lactate

level (Fig. 3b) in TGF- β 1-stimulated NRCFs. Importantly, 3PO diminished the TGF- β 1-stimulated α -SMA gene expression (Fig. 3c), a marker of cardiac fibroblast activation. 3PO was also able to reverse the differentiated phenotypes in mRNAs of *Col1a1* and *Col3a1* of NRCFs (Fig. 3c).

Furthermore, siRNA transfection was employed to silence *Pfkfb3* in NRCFs (Supplemental Fig. S2b). As expected, *Pfkfb3* silencing decreased the extracellular lactate levels in response to TGF- β 1 stimulation (Fig. 3d). SiRNA silencing also inhibited the protein expressions of α -SMA, collagen 1, collagen 3 (Fig. 3e), and suppressed proliferation of NRCFs upon TGF- β 1 insult (Fig. 3f). In addition, the protein level of hypoxia-inducible factor 1 α (HIF-1 α) was elevated upon TGF- β 1 insult, and this alteration was reversed by *Pfkfb3* silencing (Fig. 3g). Moreover, HIF-1 α inhibitor 2-MeOE2 attenuated the increase of α -SMA, *Col1a1*, and *Col3a1* expression in TGF- β 1-treated cardiac fibroblasts (Fig. 3h), revealing that HIF-1 α may function downstream of augmented glycolysis in regulating cardiac fibroblast activation and differentiation.

Downregulation of PFKFB3 attenuated post-MI cardiac fibrosis in mice

The roles of PFKFB3 and glycolysis in cardiac fibrosis were investigated in post-MI mice. Intraperitoneal injection of PFKFB3 inhibitor 3PO (35 mg/kg) inhibited the expressions of α -SMA, collagen 1, and collagen 3 in post-MI mice (Fig. 4a). LOX expression was markedly increased, and this alteration was attenuated by 3PO treatment (Fig. 4b). Masson's trichrome staining showed that 3PO treatment




Fig. 2 Glycolytic enzyme PFKFB3 was elevated in fibrotic cardiac fibroblasts. **a** mRNA expressions of *Hk2*, *Pfkfb3*, *Pfkf3*, and *Pkm2* in neonatal rat cardiac fibroblasts treated with TGF- β 1 (10 ng/ml, 24 h) ($n=4$). **b** PFKFB3 expressions in human cardiac tissue from ischemic patients analyzed based on a publicly available database (GSE132143). **c** *Pfkfb3* expressions in cardiac fibroblasts from mice post-infarction analyzed based on a publicly available database (GSE132143). **d** Analy-

sis of the correlation between PFKFB3 expression and the levels of fibrotic markers (*COL1A1*; *COL3A1*) based on a publicly available database (GSE132143). **e** PFKFB3 protein expression in primary adult cardiac fibroblasts isolated from mice 28 days post-myocardial infarction ($n=4$). **f** PFKFB3 protein expression in neonatal rat cardiac fibroblasts subjected to TGF- β 1 (10 ng/ml, 24 h) ($n=4$). Data were expressed as mean \pm SD. MI, myocardial infarction

suppressed cardiac fibrosis (Fig. 4c). A similar result was observed with Picosirius red staining of collagen contents under polarized light (Fig. 4d). 3PO treatment also improved cardiac functions in ejection fraction (EF%) and fractional shortening (FS%) (Fig. 4e and Table 1).

Furthermore, we silenced cardiac PFKFB3 in mice by tail vein injection of AAV9-*Pfkfb3* shRNA (Supplemental Fig. S3a). The increased levels of α -SMA, collagen 1, collagen 3, and LOX expression following MI were attenuated via *Pfkfb3* knockdown (Fig. 4f). Consistently, silencing *Pfkfb3* decreased collagen accumulation and attenuated cardiac fibrosis (Fig. 4g, h) and preserved cardiac functions of post-MI mice (Fig. 4i and Table 1).

TGF- β 1 treatment reduced the ubiquitination-mediated degradation of PFKFB3

PFKFB3 is subjected to constant proteasomal degradation via ubiquitination [22]. We hypothesized that the upregulation

of the PFKFB3 protein level was attributable to the reduction of proteasomal degradation. In the presence of CHX, an inhibitor of protein synthesis, the PFKFB3 protein level was degraded gradually over 0–12 h (Fig. 5a). Addition of a proteasomal inhibitor, MG-132, blocked the degradation of PFKFB3 (Fig. 5b). TGF- β 1 also significantly inhibited the time-dependent degradation of PFKFB3 (Fig. 5c, d). We then performed immunoprecipitation assays with an anti-PFKFB3 antibody and detected ubiquitin levels by western blotting. As expected, TGF- β 1 treatment decreased the level of ubiquitinated PFKFB3 (Fig. 5e).

TGF- β 1 promoted the interaction of PFKFB3 and deubiquitinase OTUD4

To clarify the mechanism by which TGF- β 1 suppressed PFKFB3 ubiquitylation, we employed Co-IP/MS to identify PFKFB3-binding proteins. We focused on deubiquitinases and found that OTUD4 was a potential interaction




Fig. 3 Inhibition of PFKFB3-involved glycolysis alleviated the fibrotic phenotypes in TGF- β 1-induced cardiac fibroblasts. **a** Phosphofruktokinase activity stimulated with TGF- β 1 (10 ng/ml, 24 h) in the presence of 3PO (20 μ M, 24 h) ($n=6$). **b** Lactate levels in cultural supernatant of neonatal rat cardiac fibroblasts subjected to TGF- β 1 (10 ng/ml, 24 h) with or without 3PO (20 μ M, 24 h) ($n=6$). **c** mRNA expressions of α -SMA, *Coll1a1*, *Col3a1* in neonatal rat cardiac fibroblasts stimulated by TGF- β 1 (10 ng/ml) in the presence or absence of 3PO (20 μ M) for 24 h ($n=6$). **d** Lactate levels in cultural supernatant of neonatal rat cardiac fibroblasts transfected with scramble siRNA or *Pfkfb3* siRNA

($n=6$). **e** Protein expressions of α -SMA, collagen 1, and collagen 3 in neonatal rat cardiac fibroblasts transfected with scramble siRNA or *Pfkfb3* siRNA ($n=4$). **f** Cell growth of neonatal rat cardiac fibroblasts incubated with TGF- β 1 (10 ng/ml, 24 h) transfected with scramble siRNA or *Pfkfb3* siRNA ($n=6$). **g** HIF-1 α protein level in TGF- β 1-treated neonatal rat cardiac fibroblasts transfected with *Pfkfb3* siRNA ($n=4$). **h** mRNA expressions of α -SMA, *Coll1a1*, *Col3a1* in TGF- β 1-treated neonatal rat cardiac fibroblasts treated with HIF-1 α inhibitor 2-MeOE2 ($n=6$). Data were expressed as mean \pm SD. HIF-1 α , hypoxia-inducible factor 1 α ; PFK, phosphofruktokinase

protein of PFKFB3 in NRCFs (Fig. 6a, Supplemental Table S3). In 39 human organ fibrosis databases, OTUD4 expression was positively correlated with PFKFB3 in SEEK co-expression database (<https://seek.princeton.edu/seek/>) (Fig. 6b). More importantly, surface plasmon resonance showed that OTUD4 exhibited a strong binding affinity to PFKFB3 with an estimated equilibrium

dissociation constant of 250 nM (Fig. 6c). Co-IP assay demonstrated that TGF- β 1 treatment promoted the interaction of endogenous PFKFB3 and OTUD4 (Fig. 6d, e). Consistently, immunofluorescence examination (Fig. 6f) and PLA assay (Fig. 6g) showed the enhanced interaction between OTUD4 and PFKFB3 in TGF- β 1 treated NRCFs.




Fig. 4 Downregulation of PFKFB3 attenuated post-MI cardiac fibrosis in mice. **a–e** Protein expression of α -SMA, collagen type 1, collagen type 3 (**a**, $n=4$), LOX expression (**b**, scar bar: 50 μ m, $n=4$), Masson's staining (**c**, scar bar: 1 mm (left) and 500 μ m (right), $n=4$), picosirius red staining viewed under polarized light (**d**, scar bar: 50 μ m, $n=4$) and representative M-mode images by echocardiography (**e**, $n=6$) of the hearts from mice 28 days post-myocardial infarction with 3PO administration. **f–i** The mice were injected with AAV9-*Pfkfb3* shRNA

or AAV9-NC prior to LAD ligation surgery. The levels of α -SMA, collagen type 1, collagen type 3 and LOX (**f**, bar: 100 μ m, $n=4$), picosirius red staining imaged under polarized light (**g**, scar bar: 50 μ m, $n=4$), Masson's staining (**h**, scar bar: 500 μ m, $n=4$), and representative M-mode images by echocardiography (**i**, $n=6$) of the hearts were assayed 4 weeks post-MI. Data were expressed as mean \pm SD. MI, myocardial infarction

TGF- β 1 promoted PFKFB3 stability dependent on OTUD4

To further clarify the role of OTUD4 on PFKFB3 stability and fibrotic phenotypes, we knocked down OTUD4

in NRCFs with siRNA (Supplemental Fig. S4a). Results showed that TGF- β 1 treatment could reduce the ubiquitination level of PFKFB3, and this process was blocked by OTUD4 knockdown (Fig. 7a). Similarly, up-regulated PFKFB3 protein level and enzyme activity induced by

Table 1 Echocardiographic parameters

Parameter	Sham	MI	MI+3PO	Sham + AAV9-NC	MI+ AAV9-NC	MI+ AAV9- <i>Pfkfb3</i> shRNA
LV ejection fraction (%)	62.10 ± 3.48	36.24 ± 7.57 ^a	57.58 ± 10.15 ^b	60.55 ± 2.73	44.8 ± 2.81 ^c	61.33 ± 2.42 ^d
LV fraction shortening (%)	32.88 ± 2.63	17.19 ± 3.99 ^a	30.11 ± 6.99 ^b	31.62 ± 1.84	21.82 ± 1.48 ^c	32.33 ± 1.81 ^d
LV mass (mg)	72.33 ± 20.56	81.68 ± 23.33	86.36 ± 16.77	76.02 ± 19.92	94.11 ± 6.69	91.25 ± 16.29
LV diastolic volume (μL)	60.98 ± 13.89	65.96 ± 13.10	57.16 ± 12.31	54.03 ± 13.34	64.28 ± 11.81	61.54 ± 8.20
LV systolic volume (μL)	22.88 ± 4.60	42.14 ± 10.21 ^a	24.59 ± 9.81 ^b	21.46 ± 6.09	35.77 ± 7.72 ^c	23.68 ± 2.50 ^d
LV internal dimension (diastole, mm)	3.75 ± 0.36	3.88 ± 0.34	3.66 ± 0.31	3.56 ± 0.38	3.84 ± 0.32	3.78 ± 0.20
LV internal dimension (systole, mm)	2.51 ± 0.20	3.21 ± 0.33 ^a	2.56 ± 0.38 ^b	2.44 ± 0.29	3.01 ± 0.30 ^c	2.56 ± 0.11 ^d
Interventricular septal dimension (diastole, mm)	0.69 ± 0.14	0.75 ± 0.09	0.92 ± 0.14	0.84 ± 0.14	0.93 ± 0.15	0.91 ± 0.15
Interventricular septal dimension (systole, mm)	1.00 ± 0.20	0.88 ± 0.09	1.22 ± 0.09 ^b	1.14 ± 0.10	1.15 ± 0.08	1.34 ± 0.12 ^d
LV posterior wall dimension (diastole, mm)	0.71 ± 0.24	0.72 ± 0.15	0.75 ± 0.13	0.73 ± 0.22	0.76 ± 0.13	0.76 ± 0.12
LV posterior wall dimension (systole, mm)	1.08 ± 0.19	0.90 ± 0.25	1.10 ± 0.15	0.91 ± 0.14	0.84 ± 0.13	1.06 ± 0.13 ^d

LV left ventricular, MI myocardial infarction

^a*p* < 0.05 vs. Sham

^b*p* < 0.05 vs. MI

^c*p* < 0.05 vs. sham + AAV9-NC

^d*p* < 0.05 vs. MI + AAV9-NC

TGF-β1 were reversed when OTUD4 was knocked down (Fig. 7b and c). OTUD4 knockdown also reduced lactate production (Fig. 7d). In agreement, OTUD4 knockdown inhibited the expressions of α-SMA, collagen 1, and collagen 3 and the proliferation of NRCFs upon TGF-β1 insult (Fig. 7e–h).

Discussion and conclusion

In the present study, we found that the TGF-β1-induced cardiac fibroblast activation and differentiation were associated with PFKFB3-driven glycolysis. Pharmacological and genetic inhibition of PFKFB3 decreased TGF-β1-induced profibrotic phenotypes in NRCFs and attenuated ischemia-induced cardiac fibrosis in mice. We further identified the deubiquitinase OTUD4 as a new binding protein of PFKFB3. TGF-β1 treatment blunted PFKFB3 degradation via OTUD4-mediated deubiquitylation to maintain a high glycolytic phenotype in NRCFs. Our work highlighted that targeting glycolysis-based therapy via inhibition of PFKFB3 served as an alternative way to mitigate cardiac fibrosis.

Cardiac fibrosis occurs in the end stage of MI and impairs cardiac function. TGF-β1 is one of the most important fibrogenic growth factors in cardiac fibrosis. Targeting TGF-β1 is considered an approved therapy for alleviating fibrosis [25]. However, TGF-β inhibition incurred higher mortality and left ventricular dilatation in post-MI mice [26].

Consistently, targeting small mothers against decapentaplegic 3 (SMAD3), the downstream pathway of TGF-β, increased the myofibroblast density [27]. This evidence corroborates that direct inhibiting TGF-β/SMAD signaling leads to more harm than good. As the heart is an energy-intensive organ, perturbations in cardiac energy metabolism are associated with several cardiovascular diseases, such as heart failure and ischemic heart disease [28]. TGF-β1 is also proposed as a metabolic regulator [11]. Hence, we focused on metabolic alternation in cardiac fibrosis. We observed that elevated glycolysis was a crucial character in TGF-β1-stimulated cardiac fibroblasts, in line with the previous reports in several fibrotic diseases [14, 21, 29, 30].

Augmented glycolysis can provide considerable biosynthetic intermediates and energy to support enhanced protein synthesis and rapid proliferation during fibrosis [31]. The metabolic intermediate 3-phosphoglyceric acid contributes to serine and glycine synthesis for collagen production [32]. Lactate, the end-product of glycolysis, can promote collagen hydroxylation [33]. Augmented glycolysis promoted the rise of intermediate succinate to stabilize the transcription factor HIF-1α [14]. In line with this, we found the accumulation of HIF-1α in fibrotic cardiac fibroblasts. Moreover, *Pfkfb3* silencing attenuated the accumulation of HIF-1α upon TGF-β1 insult, suggesting HIF-1α was the downstream of augmented glycolysis. HIF-1α was considered to be required for the activation and differentiation of fibroblasts by binding to the specific responsive element within the α-SMA promoter [14]. Consistently, we observed that HIF-1α inhibition




Fig. 5 TGF- β 1 treatment reduced the ubiquitination-mediated degradation of PFKFB3. **a** Degradation of PFKFB3 in neonatal rat cardiac fibroblasts treated with cycloheximide (10 μ M). **b** Degradation of PFKFB3 in neonatal rat cardiac fibroblasts treated with cycloheximide (10 μ M) and MG132 (10 μ M). **c** Degradation of PFKFB3 in neonatal rat cardiac fibroblasts treated with cycloheximide (10 μ M) and TGF- β 1 (10 ng/ml). **d** Comparison of degradation of PFKFB3 in

neonatal rat cardiac fibroblasts treated with cycloheximide (10 μ M), MG132 (10 μ M), or TGF- β 1 (10 ng/ml), the level of PFKFB3 in 0 h is normalized as 100% ($n=4$). **e** Ubiquitylation of PFKFB3 purified with immunoprecipitation from neonatal rat cardiac fibroblasts treated with or without TGF- β 1 (10 ng/ml, 24 h) ($n=4$). Data were expressed as mean \pm SD. CHX, cycloheximide

attenuated cardiac fibroblast activation and collagen production in TGF- β 1-treated cardiac fibroblasts, revealing that HIF-1 α -mediated transcription regulation was a critical mechanism through which glycolysis affected cardiac fibrogenesis. Suppressing glycolysis is reported to ameliorate fibrosis in the kidney [29], lung [14], and liver [21]. In line with this, we observed that blocking PFKFB3-involved glycolysis attenuated ECM deposition and fibroblast proliferation to prevent cardiac fibrosis following ischemia.

Glycolytic flux is controlled by the expression or the enzyme activity of key enzymes in the glycolytic pathway. However, direct blockade of glycolysis in the heart may incur some unfavorable effects [18]. 2-deoxy-D-glucose (2-DG), targeting first rate-limiting glycolytic enzyme HK, alleviated post-MI cardiac fibrosis without a reverse of cardiac functions [30]. Being different from the three rate-limiting glycolytic enzymes, PFKFB3 indirectly regulates the glycolytic rate by producing F2,6BP, an allosteric activator of PFK1 [16]. PFKFB3 played a positive role in the normal heart [34]. Elevated PFKFB3 protected cardiomyocytes against hypoxia [35].

However, in long term, PFKFB3-driven aerobic glycolysis accelerated cardiac hypertrophy [35]. In the present study, we found that the overexpression of PFKFB3 in cardiac fibroblasts might be an important feature of cardiac fibrosis post-MI. The PFKFB3 inhibitor 3PO was demonstrated to reduce glycolysis only partially, without causing antiglycolytic effects in normal tissue [14, 21]. It is reported that a mild ramping down of glycolysis by 3PO was able to alleviate lung fibrosis [14]. Similarly, 3PO administration could suppress the development of endothelial-to-mesenchymal transition-associated cardiac fibrosis [36]. In line with these, we observed that pharmacological and genetic inhibition of PFKFB3 attenuated cardiac fibrosis and preserved the cardiac functions indicated by the increased ejection fraction and fraction shortening of post-infarction hearts in mice. Notably, it could not rule out the possibility that the action of 3PO on other cardiac cell types, such as cardiomyocytes and infiltrating macrophages, may also contribute to its in vivo effectiveness. Additionally, systemic injection of AAV-9 shRNA provided highly efficient transduction in the heart, but there was no selectivity in individual




Fig. 6 TGF- β 1 promoted the interaction of PFKFB3 and deubiquitinase OTUD4. **a** Mass spectrum information of razor peptides to OTUD4 found in immunoprecipitated PFKFB3 complex extracted from TGF- β 1 treated neonatal rat cardiac fibroblasts. **b** OTUD4 rank in proteins correlated with PFKFB3 in 39 human organ fibrosis samples from SEEK database. **c** Surface plasma resonance analysis between human recombinant PFKFB3 protein and human recombinant OTUD4 protein. **d** PFKFB3 protein level in precipitated OTUD4 from neonatal rat cardiac fibroblasts incubated with or without TGF- β 1 (10 ng/ml, 24 h) ($n=4$). **e**

OTUD4 protein level in precipitated PFKFB3 from neonatal rat cardiac fibroblasts incubated with or without TGF- β 1 (10 ng/ml, 24 h) ($n=4$). **f** Immunofluorescence detection of HA-OTUD4 co-localized with Flag-PFKFB3 in neonatal rat cardiac fibroblasts insulted with TGF- β 1 (10 ng/ml, 24 h) ($n=4$). Scar bar: 5 μ m. **g** Proximity ligation assay (PLA) of OTUD4 and PFKFB3 in neonatal rat cardiac fibroblasts incubated with TGF- β 1 (10 ng/ml, 24 h) ($n=4$). Scar bar: 5 μ m. Data were expressed as mean \pm SD

cardiac cell types. Therefore, further research on the target depletion of PFKFB3 using cardiac fibroblast-specific knockout mice or AAV-9 vectors carrying myofibroblast-specific promoters would be required.

PFKFB3 level is regulated by multiple aspects, including transcription, translation, post-translational modifications, and protein degradation [20–22, 37, 38]. As reported, TGF- β 1 treatment regulates the transcription of *Pfkfb3* mRNA




Fig. 7 TGF-β1 promoted PFKFB3 stability dependent on OTUD4. **a** Ubiquitylation of PFKFB3 purified with immunoprecipitation from neonatal rat cardiac fibroblasts transfected with scramble siRNA or *Otud4* siRNA and treated with or without TGF-β1 (10 ng/ml, 24 h) ($n=4$). **b** PFKFB3 protein expression in neonatal rat cardiac fibroblasts transfected with scramble siRNA or *Otud4* siRNA and treated with or without TGF-β1 (10 ng/ml, 24 h) ($n=4$). **c** and **d**, Phosphof-

ructokinase activity (**c**, $n=6$), and lactate release (**d**, $n=6$) of neonatal rat cardiac fibroblasts transfected with *Otud4* siRNA in response to TGF-β1 (10 ng/ml, 24 h). **e–h**, Protein expressions of α-SMA (**e**, $n=4$), collagen 1 (**f**, $n=4$), collagen 3 (**g**, $n=4$), and cell growth (**h**, $n=6$) in neonatal rat cardiac fibroblasts transfected with *Otud4* siRNA upon TGF-β1 insult. Data were expressed as mean ± SD

in both cancer cells and fibrotic lung myofibroblasts [14, 39]. Similarly, we observed that in TGF-β1-induced cardiac fibroblasts, the mRNA expression of *Pfkfb3* was increased. Besides the transcriptional regulation, ubiquitin-mediated proteasomal degradation controls the PFKFB3 protein level [22, 40]. Increasing ubiquitylation of PFKFB3 promoted its degradation and contributed to inhibiting cell proliferation [40]. Disrupting PFKFB3 stability by accelerating its degradation could inhibit glycolysis to limit the fibrotic process [36]. Consistently, our study showed that TGF-β1 treatment

decreased the level of PFKFB3 ubiquitylation and stabilized PFKFB3. It is suggested that ubiquitin-mediated degradation is involved in the elevation of PFKFB3 protein levels in activated cardiac fibroblasts.

To further explore the mechanism by which TGF-β1 suppressed PFKFB3 ubiquitylation, we found that OTUD4, a deubiquitinase, was a PFKFB3-binding protein and enhanced the stability of PFKFB3. Deubiquitylation has attracted increasing attention regarding the regulation of aerobic glycolysis through facilitating protein stability and activity of

some glycolytic enzymes [41]. OTUD4, which belongs to the OTU deubiquitinase family. OTU deubiquitinases can block ubiquitin-dependent protein degradation and are involved in various pathways and processes, like profibrotic signaling, proliferation, and glucose metabolism [42–44]. OTUD4 has been reported as a positive regulator of TGF- β signaling [45]. Herein, we showed that TGF- β 1 promoted the interaction of OTUD4 and PFKFB3. Through deubiquitination, OTUD4 stabilized the PFKFB3 level and promoted TGF- β 1-induced fibroblast activation.

An increased total amount of PFKFB3 facilitates its various post-translational modifications [37, 38]. For example, PFKFB3 can be activated by AMP-activated protein kinase (AMPK)-involved phosphorylation, leading to the increase of glycolytic flux to promote cell proliferation [37, 46]. As a master energy regulator, AMPK activation is known to be involved in the regulation of cardiac fibrosis post-ischemia via diverse mechanisms [47]. As reported, AMPK can activate the TGF- β 1 pathway to promote the formation of a mature collagen scar during early post-MI remodeling. However, in adverse post-MI heart remodeling, AMPK activation exerts an anti-fibrotic effect [47]. Additionally, O-GlcNAcylation, as the sensor of oxygen and glucose, is known as a key regulator of glycolytic pathways and is involved in regulating myocardial hypertrophy or fibrosis [48–50]. Evidence showed that O-GlcNAcylation of PFKFB3 was demonstrated to be required for tumor cell proliferation under hypoxia conditions [38]. In line with this, we also observed the increased O-GlcNAcylation of PFKFB3 in fibrotic cardiac fibroblasts (Supplemental Fig. S5a). Further study is required to uncover the role of PFKFB3 or other glycolytic enzymes in regulating cardiac fibrosis post-ischemia from the perspective of post-translational modifications.

In conclusion, we demonstrated that the glycolytic enzyme PFKFB3 was up-regulated to augment glycolysis in fibrotic cardiac fibroblasts. Deubiquitinase OTUD4 bonded to PFKFB3 and enhanced PFKFB3 stability via deubiquitylation upon TGF- β 1 treatment. Blockade of PFKFB3 contributed to alleviating fibrotic phenotypes and ameliorating ischemia-induced cardiac fibrosis. Together, our research provided evidence of treating cardiac fibrosis through the regulation of glycolytic reprogramming via targeting PFKFB3.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00109-023-02323-6>.

Author contribution Jia Li, Lian-Wen Qi, and Zongxiang Tang conceived the original idea and designed the study. Feizuo Wang, Yuan-Ming Fan, Xinyao Zhang, Chao Ma, Keke Jia, and Wei Zhou performed the experiments. Lian-Wen Qi, Jia Li, Xiaojian Yin, and Feizuo Wang prepared the manuscript. All authors approved the final version of the manuscript.

Funding This work was financially supported by the National Natural Science Foundation of China (Grant No. 82003978, 81903823). We acknowledged the Public platform of the State Key Laboratory of

Natural Medicines of China Pharmaceutical University for supplying a small animal ultrasound imaging system (FUJIFILM VisualSonics Vevo 3100 LT) and thanked Li Guo for help with ultrasound imaging and technical support. We also thank Shanghai Bioprofile Technology Company Ltd. for the technical support in mass spectroscopy.

Data availability The authors declare that all data supporting the findings of this study are available within the article or from the corresponding author upon reasonable request.

Declarations

Ethics approval The animal care and all experimental procedures were approved by the Animal Ethics Committee of the Nanjing University of Chinese Medicine and the Animal Ethics Committee of China Pharmaceutical University.

Consent to participate Not applicable.

Consent for publication Not applicable.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References


- Porter KE, Turner NA (2009) Cardiac fibroblasts: at the heart of myocardial remodeling. *Pharmacol Ther* 123:255–278. <https://doi.org/10.1016/j.pharmthera.2009.05.002>
- Talman V, Ruskoaho H (2016) Cardiac fibrosis in myocardial infarction—from repair and remodeling to regeneration. *Cell Tissue Res* 365:563–581. <https://doi.org/10.1007/s00441-016-2431-9>
- DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. *Cell Metab* 7:11–20. <https://doi.org/10.1016/j.cmet.2007.10.002>
- Luczak ED, Wu Y, Granger JM, Joiner MA, Wilson NR, Gupta A, Umapathi P, Murphy KR, Reyes Gaido OE, Sabet A et al (2020) Mitochondrial CaMKII causes adverse metabolic reprogramming and dilated cardiomyopathy. *Nat Commun* 11:4416. <https://doi.org/10.1038/s41467-020-18165-6>
- Faubert B, Solmonson A, DeBerardinis RJ (2020) Metabolic reprogramming and cancer progression. *Science* 368:eaaw5473. <https://doi.org/10.1126/science.aaw5473>
- DeNicola GM, Cantley LC (2015) Cancer's fuel choice: new flavors for a picky eater. *Mol Cell* 60:514–523. <https://doi.org/10.1016/j.molcel.2015.10.018>
- Kashihara T, Mukai R, Oka SI, Zhai P, Nakada Y, Yang Z, Mizushima W, Nakahara T, Warren JS, Abdellatif M et al (2022) YAP mediates compensatory cardiac hypertrophy through aerobic glycolysis

- in response to pressure overload. *J Clin Invest* 132:e150595. <https://doi.org/10.1172/JCI150595>
8. Rees ML, Subramaniam J, Li Y, Hamilton DJ, Frazier OH, Taegtmeier H (2015) A PKM2 signature in the failing heart. *Biochem Biophys Res Commun* 459:430–436. <https://doi.org/10.1016/j.bbrc.2015.02.122>
 9. Wang T, Marquardt C, Foker J (1976) Aerobic glycolysis during lymphocyte proliferation. *Nature* 261:702–705. <https://doi.org/10.1038/261702a0>
 10. Bernard K, Logsdon NJ, Ravi S, Xie N, Persons BP, Rangarajan S, Zmijewski JW, Mitra K, Liu G, Darley-Usmar VM et al (2015) Metabolic reprogramming is required for myofibroblast contractility and differentiation. *J Biol Chem* 290:25427–25438. <https://doi.org/10.1074/jbc.M115.646984>
 11. Zhao X, Kwan JYY, Yip K, Liu PP, Liu FF (2020) Targeting metabolic dysregulation for fibrosis therapy. *Nat Rev Drug Discov* 19:57–75. <https://doi.org/10.1038/s41573-019-0040-5>
 12. Im MJ, Freshwater MF, Hoopes JE (1976) Enzyme activities in granulation tissue: energy for collagen synthesis. *J Surg Res* 20:121–125. [https://doi.org/10.1016/0022-4804\(76\)90108-6](https://doi.org/10.1016/0022-4804(76)90108-6)
 13. Opie LH (1990) Myocardial ischemia–metabolic pathways and implications of increased glycolysis. *Cardiovasc Drugs Ther* 4:777–790. <https://doi.org/10.1007/BF00051275>
 14. Xie N, Tan Z, Banerjee S, Cui H, Ge J, Liu RM, Bernard K, Thannickal VJ, Liu G (2015) Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis. *Am J Respir Crit Care Med* 192:1462–1474. <https://doi.org/10.1164/rccm.201504-0780OC>
 15. Wu R, Smeele KM, Wyatt E, Ichikawa Y, Eerbeek O, Sun L, Chawla K, Hollmann MW, Nagpal V, Heikkinen S et al (2011) Reduction in hexokinase II levels results in decreased cardiac function and altered remodeling after ischemia/reperfusion injury. *Circ Res* 108:60–69. <https://doi.org/10.1161/CIRCRESAHA.110.223115>
 16. Manzano A, Rosa JL, Ventura F, Pérez JX, Nadal M, Estivill X, Ambrosio S, Gil J, Bartrons R (1998) Molecular cloning, expression, and chromosomal localization of a ubiquitously expressed human 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene (PFKFB3). *Cytogenet Cell Genet* 83:214–217. <https://doi.org/10.1159/000015181>
 17. Rider MH, Bertrand L, Vertommen D, Michels PA, Rousseau GG, Hue L (2004) 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. *Biochem J* 381:561–579. <https://doi.org/10.1042/BJ20040752>
 18. Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquière B, Cauwenberghs S, Kuchnio A, Wong BW, Quaegebeur A, Goveia J et al (2014) Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. *Cell Metab* 19:37–48. <https://doi.org/10.1016/j.cmet.2013.11.008>
 19. Houddane A, Bultot L, Novellademunt L, Johanns M, Gueuning MA, Vertommen D, Coulie PG, Bartrons R, Hue L, Rider MH (2017) Role of Akt/PKB and PFKFB isoenzymes in the control of glycolysis, cell proliferation and protein synthesis in mitogen-stimulated thymocytes. *Cell Signal* 34:23–37. <https://doi.org/10.1016/j.cellsig.2017.02.019>
 20. Minchenko A, Leshchinsky I, Opentanova I, Sang N, Srinivas V, Armstead V, Caro J (2002) Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. *J Biol Chem* 277:6183–6187. <https://doi.org/10.1074/jbc.M110978200>
 21. Mejias M, Gallego J, Naranjo-Suarez S, Ramirez M, Pell N, Manzano A, Suñer C, Bartrons R, Mendez R, Fernandez M (2020) CPEB4 increases expression of PFKFB3 to induce glycolysis and activate mouse and human hepatic stellate cells, promoting liver fibrosis. *Gastroenterology* 159:273–288. <https://doi.org/10.1053/j.gastro.2020.03.008>
 22. Herrero-Mendez A, Almeida A, Fernández E, Maestre C, Moncada S, Bolaños JP (2009) The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. *Nat Cell Biol* 11:747–752. <https://doi.org/10.1038/ncb1881>
 23. Gao E, Lei YH, Shang X, Huang ZM, Zuo L, Boucher M, Fan Q, Chuprun JK, Ma XL, Koch WJ (2010) A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. *Circ Res* 107:1445–1453. <https://doi.org/10.1161/CIRCRESAHA.110.223925>
 24. Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann WH (1993) Identification of functional angiotensin II receptors on rat cardiac fibroblasts. *Circulation* 88:2849–2861. <https://doi.org/10.1161/01.cir.88.6.2849>
 25. Spagnolo P, Kropski JA, Jones MG, Lee JS, Rossi G, Karamitsakos T, Maher TM, Tzouveleakis A, Ryerson CJ (2021) Idiopathic pulmonary fibrosis: disease mechanisms and drug development. *Pharmacol Ther* 222:107798. <https://doi.org/10.1016/j.pharmthera.2020.107798>
 26. Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, Lonning S, Ling H, Ertl G, Bauersachs J (2008) Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. *Basic Res Cardiol* 103:485–492. <https://doi.org/10.1007/s00395-008-0739-7>
 27. Bujak M, Ren G, Kweon HJ, Dobaczewski M, Reddy A, Taffet G, Wang XF, Frangogiannis NG (2007) Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. *Circulation* 116:2127–2138. <https://doi.org/10.1161/CIRCULATIONAHA.107.704197>
 28. Fillmore N, Mori J, Lopaschuk GD (2014) Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. *Br J Pharmacol* 171:2080–2090. <https://doi.org/10.1111/bph.12475>
 29. Yu H, Zhu J, Chang L, Liang C, Li X, Wang W (2021) 3-Bromopyruvate decreased kidney fibrosis and fibroblast activation by suppressing aerobic glycolysis in unilateral ureteral obstruction mice model. *Life Sci* 272:119206. <https://doi.org/10.1016/j.lfs.2021.119206>
 30. Chen ZT, Gao QY, Wu MX, Wang M, Sun RL, Jiang Y, Guo Q, Guo DC, Liu CY, Chen SX et al (2021) Glycolysis inhibition alleviates cardiac fibrosis after myocardial infarction by suppressing cardiac fibroblast activation. *Front Cardiovasc Med* 8:701745. <https://doi.org/10.3389/fcvm.2021.701745>
 31. Henderson J, O'Reilly S (2021) The emerging role of metabolism in fibrosis. *Trends Endocrinol Metab* 32:639–653. <https://doi.org/10.1016/j.tem.2021.05.003>
 32. de Paz-Lugo P, Lupiáñez JA, Meléndez-Hevia E (2018) High glycine concentration increases collagen synthesis by articular chondrocytes in vitro: acute glycine deficiency could be an important cause of osteoarthritis. *Amino Acids* 50:1357–1365. <https://doi.org/10.1007/s00726-018-2611-x>
 33. Savolainen ER, Leo MA, Timpl R, Lieber CS (1984) Acetaldehyde and lactate stimulate collagen synthesis of cultured baboon liver myofibroblasts. *Gastroenterology* 87:777–787
 34. Donthi RV, Ye G, Wu C, McClain DA, Lange AJ, Epstein PN (2004) Cardiac expression of kinase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase inhibits glycolysis, promotes hypertrophy, impairs myocyte function, and reduces insulin sensitivity. *J Biol Chem* 279:48085–48090. <https://doi.org/10.1074/jbc.M405510200>
 35. Wang Q, Donthi RV, Wang J, Lange AJ, Watson LJ, Jones SP, Epstein PN (2008) Cardiac phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase increases glycolysis, hypertrophy, and myocyte resistance to hypoxia. *Am J Physiol Heart Circ Physiol* 294:H2889–H2897. <https://doi.org/10.1152/ajpheart.91501.2007>

36. Zeng H, Pan T, Zhan M, Hailiwu R, Liu B, Yang H, Li P (2022) Suppression of PFKFB3-driven glycolysis restrains endothelial-to-mesenchymal transition and fibrotic response. *Signal Transduct Target Ther* 7:303. <https://doi.org/10.1038/s41392-022-01097-6>
37. Li FL, Liu JP, Bao RX, Yan G, Feng X, Xu YP, Sun YP, Yan W, Ling ZQ, Xiong Y et al (2018) Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis. *Nat Commun* 9:508. <https://doi.org/10.1038/s41467-018-02950-5>
38. Lei Y, Chen T, Li Y, Shang M, Zhang Y, Jin Y, Yu Q, Guo F, Wang T (2020) O-GlcNAcylation of PFKFB3 is required for tumor cell proliferation under hypoxia. *Oncogenesis* 9:21. <https://doi.org/10.1038/s41389-020-0208-1>
39. Rodríguez-García A, Samsó P, Fontova P, Simon-Molas H, Manzano A, Castaño E, Rosa JL, Martínez-Outshoorn U, Ventura F, Navarro-Sabaté À, Bartrons R (2017) TGF- β 1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells. *FEBS J* 284:3437–3454. <https://doi.org/10.1111/febs.14201>
40. Liu X, Li J, Wang Z, Meng J, Wang A, Zhao X, Xu Q, Cai Z, Hu Z (2021) KDM2A targets PFKFB3 for ubiquitylation to inhibit the proliferation and angiogenesis of multiple myeloma cells. *Front Oncol* 11:653788. <https://doi.org/10.3389/fonc.2021.653788>
41. Xie Y, Wang M, Xia M, Guo Y, Zu X, Zhong J (2022) Ubiquitination regulation of aerobic glycolysis in cancer. *Life Sci* 292:120322. <https://doi.org/10.1016/j.lfs.2022.120322>
42. Du T, Li H, Fan Y, Yuan L, Guo X, Zhu Q, Yao Y, Li X, Liu C, Yu X et al (2019) The deubiquitylase OTUD3 stabilizes GRP78 and promotes lung tumorigenesis. *Nat Commun* 10:2914. <https://doi.org/10.1038/s41467-019-10824-7>
43. Zhang Z, Fan Y, Xie F, Zhou H, Jin K, Shao L, Shi W, Fang P, Yang B, Dam H et al (2017) Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7. *Nat Commun* 8:2116. <https://doi.org/10.1038/s41467-017-02029-7>
44. Zhou N, Qi H, Liu J, Zhang G, Liu J, Liu N, Zhu M, Zhao X, Song C, Zhou Z et al (2022) Deubiquitinase OTUD3 regulates metabolism homeostasis in response to nutritional stresses. *Cell Metab* 34:1023–41.e8. <https://doi.org/10.1016/j.cmet.2022.05.005>
45. Jaynes PW, Iyengar PV, Lui SKL, Tan TZ, Vasilevski N, Wright SCE, Verdile G, Jeyasekharan AD, Eichhorn PJA (2020) OTUD4 enhances TGF β signalling through regulation of the TGF β receptor complex. *Sci Rep* 10:15725. <https://doi.org/10.1038/s41598-020-72791-0>
46. Doménech E, Maestre C, Esteban-Martínez L, Partida D, Pascual R, Fernández-Miranda G, Seco E, Campos-Olivas R, Pérez M, Megias D et al (2015) AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest. *Nat Cell Biol* 17:1304–1316. <https://doi.org/10.1038/ncb3231>
47. Daskalopoulos EP, Dufey C, Bertrand L, Beauloye C, Horman S (2016) AMPK in cardiac fibrosis and repair: actions beyond metabolic regulation. *J Mol Cell Cardiol* 91:188–200. <https://doi.org/10.1016/j.yjmcc.2016.01.001>
48. Bacigalupa ZA, Bhadiadra CH, Reginato MJ (2018) O-GlcNAcylation: key regulator of glycolytic pathways. *J Bioenerg Biomembr* 50:189–198. <https://doi.org/10.1007/s10863-018-9742-3>
49. Gélinas R, Mailleux F, Dontaine J, Bultot L, Demeulder B, Ginion A, Daskalopoulos EP, Esfahani H, Dubois-Deruy E, Lauzier B et al (2018) AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation. *Nat Commun* 9:374. <https://doi.org/10.1038/s41467-017-02795-4>
50. Prakoso D, Lim SY, Erickson JR, Wallace RS, Lees JG, Tate M, Kiriazis H, Donner DG, Henstridge DC, Davey JR et al (2022) Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart. *Cardiovasc Res* 118:212–225. <https://doi.org/10.1093/cvr/cvab043>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Feizuo Wang^{1,2} · Xiaojian Yin² · Yuan-Ming Fan² · Xinyao Zhang² · Chao Ma¹ · Keke Jia¹ · Wei Zhou² · Zongxiang Tang¹ · Lian-Wen Qi² · Jia Li¹ 

¹ School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, No. 138 Xianlin Avenue, Nanjing 210023, Jiangsu, China

² State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, No. 639 Longmian Road, Nanjing 210009 Jiangsu, China